The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
What has serotonin to do with depression?
Open accessAbstract
The "serotonin hypothesis" of clinical depression is almost 50 years old. At its simplest, the hypothesis proposes that diminished activity of serotonin pathways plays a causal role in the pathophysiology of depression. This notion was based on the depressogenic effects of amine depleting agents such as reserpine, as well as the actions of antidepressant drugs such as monoamine oxidase inhibitors and tricyclic antidepressants, discovered by clinical serendipity, but later found in animal experimental studies to potentiate the effects of serotonin and other monoamines at the synapse 1. This pattern of theory making – moving from the pharmacological actions of drugs with some efficacy in treatment to biochemical notions of causation – has been common in biological psychiatry. In such an undeveloped field this approach, though logically precarious, has been a useful heuristic and, in the case of the dopamine hypothesis of psychosis, has been strikingly upheld by advanced brain imaging techniques 2. However, the serotonin hypothesis of depression has not been clearly substantiated. Indeed, dogged by unreliable clinical biochemical findings and the difficulty of relating changes in serotonin activity to mood state, the serotonin hypothesis eventually achieved "conspiracy theory" status, whose avowed purpose was to enable industry to market selective serotonin reuptake inhibitors (SSRIs) to a gullible public 3. In biological psychiatry, pathophysiological hypotheses are not easily refuted. More often they simply seem to become irrelevant as new models of causation take their place. In an era of neural networks and systems level neuroscience, "single" neurotransmitter theories of depression look increasingly implausible. Is serotonin still worth thinking about in relation to depression? The best evidence that serotonin plays a role in the pathophysiology of depression comes from studies of "tryptophan depletion", where an acute dietary manipulation is employed to produce a transient lowering in brain serotonin activity through diminishing availability of its precursor amino acid, tryptophan. In healthy participants with no risk factors for depression, tryptophan depletion does not produce clinically significant changes in mood; however, recovered depressed patients free of medication can show brief, clinically relevant, depressive symptomatology 4. Interestingly, the same is true of recovered depressed patients undergoing catecholamine depletion with alpha-methyl-para-tyrosine 5. Overall, this evidence suggests that impairing serotonin function can cause clinical depression in some circumstances, but is neither necessary nor sufficient. In addition, the depressogenic effects of tryptophan depletion are much more apparent in people who have experienced prior episodes of depression than in those simply at high risk of illness, for example by virtue of a strong family history 6. This suggests that low serotonin function may compromise mechanisms involved in maintaining recovery from depression rather than having a primary effect to lower mood in all vulnerable people. These findings also hint at a role for diminished tryptophan availability in triggering depression, particularly in people with a previous history of illness. Interestingly, lower plasma levels of tryptophan are one of the few reasonably robust findings in patients with more severe forms of depression 7 and, more recently, have been linked to peripheral inflammation and consequent induction of the tryptophan metabolizing enzyme indoleamine 2,3-dioxygenase 8. Inflammation could therefore produce depression in vulnerable individuals by lowering plasma tryptophan and diminishing brain serotonin activity. Conceivably, such an effect could explain the diminished efficacy of SSRIs in depressed patients with high levels of inflammatory biomarkers 9. Undoubtedly, a major reason for the continuing interest in serotonin and depression is the fact that SSRIs are useful antidepressant drugs for some patients. Elegant basic studies have revealed intriguing molecular and cellular consequences of repeated SSRI administration in animals, for example increases in hippocampal cell proliferation and enhanced expression of neuroplasticity related proteins such as brain derived neurotrophic factor (BDNF) 10. However, linking such changes to resolution of the clinical depressive syndrome is challenging. More pertinent in this respect are neuropsychological studies which show that, in both healthy participants and depressed patients, administration of SSRIs leads to positive shifts in the way the brain appraises emotionally-valenced information. This effect occurs very early in treatment, prior to clinical antidepressant effects, and appears to be mediated via serotonergic innervation to limbic circuitry, particularly the amygdala 11. This work gives a new insight into how serotonin pathways may influence mood in depressed patients, that is by altering the way the brain appra
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A neural substrate of prediction and reward
Schultz, W., Dayan, P., & Montague, P. R. (1997) · Science · doi:10.1126/science.275.5306.1593 · Cited by 9,388
Cognitive Therapy of Depression
HOLLON, S. D., & BECK, A. T. (1979) · Cognitive-Behavioral Interventions · doi:10.1016/b978-0-12-404480-7.50012-5 · Cited by 4,685
The Biochemistry of Affective Disorders
Coppen, A. (1967) · British Journal of Psychiatry · doi:10.1192/bjp.113.504.1237 · Cited by 1,230 · cited 1×
“This notion was based on the depressogenic effects of amine depleting agents such as reserpine, as well as the actions of antidepressant drugs such as monoamine oxidase inhibitors and tricyclic antidepressants, discovered by clinical serendipity, but later found in animal experimental studies to potentiate the effects…”
BackgroundHowes, O. D., Kambeitz, J., Kim, E., Stahl, D., Slifstein, M., Abi-Dargham, A., & Kapur, S. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2012.169 · Cited by 967
Ruhé, H. G., Mason, N. S., & Schene, A. H. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4001949 · Cited by 861
Opponent interactions between serotonin and dopamine
Daw, N. D., Kakade, S., & Dayan, P. (2002) · Neural Networks · doi:10.1016/s0893-6080(02)00052-7 · Cited by 844
Harmer, C. J., Goodwin, G. M., & Cowen, P. J. (2009) · British Journal of Psychiatry · doi:10.1192/bjp.bp.108.051193 · Cited by 542
Self-citationThe computational neurobiology of learning and reward
Daw, N. D., & Doya, K. (2006) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2006.03.006 · Cited by 465
Serotonin and dopamine: unifying affective, activational, and decision functions.
Cools, R., Nakamura, K., & Daw, N. D. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2010.121 · Cited by 464
Wichers, M. C., Koek, G. H., Robaeys, G., Verkerk, R., Scharpé, S., & Maes, M. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001600 · Cited by 445
Relapse of depression after rapid depletion of tryptophan
Smith, K., Fairburn, C., & Cowen, P. (1997) · The Lancet · doi:10.1016/s0140-6736(96)07044-4 · Cited by 423
Self-citationUher, R., Tansey, K. E., Dew, T., Maier, W., Mors, O., Hauser, J., Dernovsek, M. Z., Henigsberg, N., Souery, D., Farmer, A., et al. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2014.14010094 · Cited by 418
Serotonin in Affective Control
Dayan, P., & Huys, Q. J. M. (2009) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.051508.135607 · Cited by 381
Pathophysiology of depression: the concept of synaptic plasticity
Duman, R. S. (2002) · European Psychiatry · doi:10.1016/s0924-9338(02)00654-5 · Cited by 361
Optogenetic Activation of Dorsal Raphe Serotonin Neurons Enhances Patience for Future Rewards
Miyazaki, K. W., Miyazaki, K., Tanaka, K. F., Yamanaka, A., Takahashi, A., Tabuchi, S., & Doya, K. (2014) · Current Biology · doi:10.1016/j.cub.2014.07.041 · Cited by 282
Serotonin, inhibition, and negative mood
Dayan, P., & Huys, Q. J. M. (2008) · PLoS Computational Biology · doi:10.1371/journal.pcbi.0040004 · Cited by 263
Low-Serotonin Levels Increase Delayed Reward Discounting in Humans
Schweighofer, N., Bertin, M., Shishida, K., Okamoto, Y., Tanaka, S. C., Yamawaki, S., & Doya, K. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.4982-07.2008 · Cited by 260
Serotonin and depression: pathophysiological mechanism or marketing myth?
COWEN, P. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.05.004 · Cited by 208
Self-citationThe role of serotonin in the regulation of patience and impulsivity
Miyazaki, K., Miyazaki, K. W., & Doya, K. (2012) · Molecular Neurobiology · doi:10.1007/s12035-012-8232-6 · Cited by 162
Berman, R., Narasimhan, M., Miller, H., Anand, A., Cappiello, A., Oren, D. A., Heninger, G. R., & Charney, D. S. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.5.395 · Cited by 122
5-HT and depression: is the glass half-full?
Sharp, T., & Cowen, P. J. (2011) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2011.02.003 · Cited by 107
Self-citationAnderson, I., Parry-billings, M., Newsholme, E., Poortmans, J., & Cowen, P. (1990) · Journal of Affective Disorders · doi:10.1016/0165-0327(90)90143-v · Cited by 54
Self-citationEven-Dar, E. (2008) · Encyclopedia of Algorithms · doi:10.1007/978-0-387-30162-4_341 · Cited by 21
Cited by
The serotonin theory of depression: a systematic umbrella review of the evidence
Moncrieff, J., Cooper, R. E., Stockmann, T., Amendola, S., Hengartner, M. P., & Horowitz, M. A. (2023) · Molecular Psychiatry · doi:10.1038/s41380-022-01661-0 · Cited by 960
Serotonin and brain function: a tale of two receptors
Carhart-Harris, R., & Nutt, D. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117725915 · Cited by 739
The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future
Carhart-Harris, R. L., & Goodwin, G. M. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.84 · Cited by 706
Correia, A. S., & Vale, N. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158493 · Cited by 350
Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression
Roseman, L., Demetriou, L., Wall, M. B., Nutt, D. J., & Carhart-Harris, R. L. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.12.041 · Cited by 230
Metadata
- Authors
- Cowen, P. J., & Browning, M.
- Venue
- World Psychiatry
- Publisher
- Wiley
- Published
- 2015-06
- Volume
- 14
- Issue
- 2
- Pages
- 158-160
- ISSN
- 1723-8617 (ISSN-L)
- OpenAlex
- W1544863932
- Cited by
- 374
- References
- 23
- FWCI
- 5.92
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.